Pasturized blood samples for transfusion compatibility testing during the coronavirus disease 2019 outbreak

Run Yao MS1, Yamei Shen BS1, Ying Tan MD1, Pengcheng Zhou MD2, Bijuan Li PhD1, Xuegong Fan PhD2,3 and Ning Li PhD1

1Department of Blood Transfusion, Xiangya Hospital, Central South University, Changsha, 410007, Hunan, China, 2Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China and 3Key Laboratory of Viral Hepatitis, Hunan Province, Changsha, China

To the Editor—In December 2019, a novel coronavirus pneumonia (COVID-19) was reported in Wuhan, China. As of April 2, 2020, 82,774 confirmed cases had been reported in China and 874,995 confirmed cases had been reported in other countries. No vaccine or antiviral therapeutics are yet available to prevent or treat COVID-19.1 Preventing infection is the current priority for disease control.

The SARS-CoV-2 virus is transmitted from person to person through droplets or direct contact.2 However, non-respiratory samples are also potential sources of COVID-19 infection.3 Virus-laden aerosols generated from blood-sample centrifugation pose risks for laboratory staff and broader nosocomial transmission.4,5 Traditional precautionary measures for infectious-sample processing include tertiary protection and operating in the biological safety cabinet. Preventive resources have been limited during this multiregional outbreak, posing huge risks to laboratory staff. Therefore, effective methods to ensure the safety of laboratory staff in low-resource settings are needed.

Pasteurization at 56°C for 30 minutes has been recommended to inactivate coronavirus, which might decrease the infectivity of samples and aerosols. To reduce infections and ensure safe and effective transfusion, we investigated the effects of pasteurization on transfusion compatibility testing.

Methods

Blood samples were collected from Xiangya Hospital, Central South University. Each sample was divided into 2 groups, an experimental group and a control group. Experimental samples were treated by pasteurization. The results of blood-group typing, irregular antibody screening, and cross-matching were compared between these 2 groups. Finally, samples of suspected SARS-CoV-2 were treated with pasteurization. Treated samples were used to test transfusion compatibility. Patients with suspected COVID-19 then received red blood cell (RBC) transfusion, and the effectiveness and safety of these transfusion were evaluated.

Results

The agglutination intensities of A, B antigens and anti-A, anti-B antibodies of the samples in the 2 groups were 4+. The forward and reverse types were consistent in the ABO blood group. In the Rh blood group, the agglutination intensity of D antigen was reduced from 4+ to between 2+ and 3+ after heat treatment (Fig. 1). Regarding the effect of heat treatment on irregular antibody screening, our results showed that the response pattern of panel cells remained unchanged after heat treatment when the agglutination intensity was negative(-), uncertain(±) or zero, and 1+, 2+, or 3+, respectively. However, the agglutination intensities of samples rating 4+ were reduced to 3+ after heat treatment (Fig. 2). Finally, no effect of heat treatment on the primary cross-matching was observed.

Our results indicated that heat treatment did not affect the results of transfusion compatibility testing. The RBC transfusion

Author for correspondence: Li Ning, E-mail: limingxy@csu.edu.cn

Cite this article: Yao R, et al. (2020). Pasteurized blood samples for transfusion compatibility testing during the coronavirus disease 2019 outbreak. Infection Control & Hospital Epidemiology, 41: 1112–1114, https://doi.org/10.1017/ice.2020.138

© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fig. 1. The results of blood group typing.

|        | Pre-treatment | Post-treatment |
|--------|---------------|---------------|
|        | A  | B  | D  | anti-A | anti-B | A  | B  | D  | anti-A | anti-B |
| A Rh(−) | ![A Rh(−) pre-treatment](image) | ![A Rh(−) post-treatment](image) |
| B Rh(−) | ![B Rh(−) pre-treatment](image) | ![B Rh(−) post-treatment](image) |
| O Rh(+) | ![O Rh(+) pre-treatment](image) | ![O Rh(+) post-treatment](image) |
| AB Rh(+) | ![AB Rh(+) pre-treatment](image) | ![AB Rh(+) post-treatment](image) |

Fig. 2. The results of irregular antibodies screening. I, II, III represent panel cells no. 1, no. 2, and no. 3, respectively (Shanghai Blood Biomedical, Shanghai, China).
India fights hard to neutralize the spread of COVID-19

Govindasamy Agoramoorthy PhD
College of Pharmacy and Health Care, Tajen University, Yanpu, Pingtung, Taiwan

To the Editor—A novel coronavirus (SARS-CoV-2) that originated in Wuhan, China, has created a pandemic across 198 countries over the first few months of 2020.1 As of April 5, 2020, India has 3,072 confirmed cases, 213 recovered persons, and 75 deaths, and more new cases are emerging rapidly. India has a huge population of >1.3 billion people, and cities such as Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, and Pune harbor millions of people who rely on public transportation. The government has aggressively promoted social distancing to minimize the spread of this virus. On a daily basis, millions of people pass through crowded train stations such as Delhi, Howrah, Sealdah, Mumbai, and Chennai. For example, the Sealdha station alone receives 1.8 million passengers, and most are from low- and middle-income families that depend on intracity transportation. Such close contact among people in highly crowded areas is potentially catastrophic for community spread of the virus. In response to this crisis, the government has created expert groups to tackle the practical problems on the ground. For example, both international and domestic flights have been grounded.2

Few detection centers to screen for SARS-CoV-2 currently exist, so a transportation chain is necessary to take samples (eg, sputum, blood, urine, and nasal swabs) from collection points to testing centers. Several days are required to obtain test results. In addition, false-positive and false-negative results can occur and must be carefully avoided. The country’s elite Indian Council of Medical Research should create more detection and observation centers to facilitate a more rapid testing process. Through agencies such as the National Institute of Virology in Pune, the government has tried to bring factual awareness regarding the virus and to eliminate the spread of false information via social media. However, this effort needs support from all healthcare NGOs to encourage people to remain calm and to act rationally.

India’s pharmaceutical industries are also facing difficulties because they obtain 70% of all active pharmaceutical ingredients from neighboring China, where the pandemic originally started.3 In addition, pharmaceutical trading companies depend on

in patients were safe and effective based on elevated 24-hour hemoglobin results or improved symptoms, with no hemolytic reactions or other adverse transfusion reactions.5

Discussion
We have demonstrated that pasteurization did not affect the results of transfusion compatibility testing and that blood transfusion based on this improved testing were safe and effective. Because the heat-inactivation method was simple, efficacious, and cost-effective, it could be employed for the protection of laboratory staff, especially in resource-poor regions during the COVID-19 pandemic.

Since virus activity testing was not available in our laboratory, we were unable to determine whether the virus can still be contagious after thermal inactivation. Reports indicated that SARS-CoV-2 was sensitive to heat and thermal inactivation could efficiently eliminate the coronavirus infectivity.6 Heat treatment causes RBCs to rupture and form RBC fragments, which may have affected the detection results. Especially in gel microcolumns, false-positive results are likely. Therefore, the classic test-tube method should be used to instead of blood-type cards to perform blood-group typing of the heat-treated samples. However, irregular antibody screening and cross-matching could be performed using the anti–human-globulin card method.

In conclusion, during the COVID-19 pandemic, pasteurization can be used to test transfusion compatibility, to protect laboratory staff from infected samples, and to ensure safe and effective transfusion. Moreover, pasteurization is convenient and quick and suitable for use in hospitals.

Acknowledgments. None.

Financial support. This study was supported by the National Natural Science Foundation of China (grant no. 81873574) and by the Emergency Special Science and Technology Plan Project of COVID-19 Epidemic of Changsha City (grant no. 37935).

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References
1. She J, Jiang J, Ye L, et al. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med 2020;9:19.
2. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020. doi: 10.1016/S0140-6736(20)30154-9.
3. Judson SD, Munster VJ. Nosocomial transmission of emerging viruses via aerosol-generating medical procedures. Viruses 2019;11(10): pii: E940.
4. Ong SWX, Tan YK, Chia PY, et al. Air, Surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA 2020. doi: 10.1001/jama.2020.3227.
5. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012;157:49–58.
6. Rabenau HF, Cinatl J, Morgenstern B, et al. Stability and inactivation of SARS coronavirus. Med Microbiol Immunol 2005;194(1–2):1–6.